Literature DB >> 14700403

Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: a prospective study using the Charlson weighted index of comorbidity.

Olivier Lesens1, Cédric Methlin, Yves Hansmann, Véronique Remy, Martin Martinot, Colm Bergin, Pierre Meyer, Daniel Christmann.   

Abstract

OBJECTIVE: To demonstrate the effectiveness of the Charlson weighted index of comorbidity (WIC) for controlling comorbidity in prospective studies focusing on mortality in patients with Staphylococcus aureus bacteremia (SAB).
DESIGN: Cohort study.
SETTING: Two tertiary-care, university-affiliated hospitals in France. PATIENTS: One hundred sixty-six inpatients 18 years or older consecutively diagnosed with SAB from May 15, 2001, to May 15, 2002.
METHODS: Patients were prospectively assessed and cases were followed by the infectious diseases consult service at least 3 months after effective antibiotic therapy completion. The Charlson WIC was computed and dichotomized into scores of fewer than 3 points and 3 or more points. Bacteremia source, acute complication due to SAB acquisition in the ICU, and inappropriate empiric antibiotic therapy were recorded. The endpoint was death due to SAB and overall mortality.
RESULTS: In univariate analysis, the Charlson WIC was able to predict overall mortality and S. aureus-related death. The following variables were found to be independently predictive of mortality due to SAB using the Cox model: an acute complication due to S. aureus (OR, 8.9; CI95, 4 to 19.7; P < .001), a Charlson WIC score of 3 or more (OR, 3; CI95, 1.3 to 5.5; P = .006), and age (OR, 1.04; CI95, 1.009 to 1.07; P < .01).
CONCLUSIONS: Comorbidity contributes to death in patients with SAB. The Charlson WIC is a good predictor of mortality in this population and may be a useful instrument to control comorbidity in studies aiming to investigate risk factors for death due to bacteremia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14700403     DOI: 10.1086/502156

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  43 in total

1.  Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis.

Authors:  Pilar Retamar; María M Portillo; María Dolores López-Prieto; Fernando Rodríguez-López; Marina de Cueto; María V García; María J Gómez; Alfonso Del Arco; Angel Muñoz; Antonio Sánchez-Porto; Manuel Torres-Tortosa; Andrés Martín-Aspas; Ascensión Arroyo; Carolina García-Figueras; Federico Acosta; Juan E Corzo; Laura León-Ruiz; Trinidad Escobar-Lara; Jesús Rodríguez-Baño
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

2.  Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia.

Authors:  R Khatib; S Saeed; M Sharma; K Riederer; M G Fakih; L B Johnson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-03       Impact factor: 3.267

3.  Microbiological features and clinical impact of the type VI secretion system (T6SS) in Acinetobacter baumannii isolates causing bacteremia.

Authors:  Jungok Kim; Ji-Young Lee; Haejeong Lee; Ji Young Choi; Dae Hun Kim; Yu Mi Wi; Kyong Ran Peck; Kwan Soo Ko
Journal:  Virulence       Date:  2017-04-27       Impact factor: 5.882

4.  Bloodstream infection caused by S. aureus in patients with cancer: a 10-year longitudinal single-center study.

Authors:  Omar Yaxmehen Bello-Chavolla; Jessica Paola Bahena-Lopez; Pamela Garciadiego-Fosass; Patricia Volkow; Alejandro Garcia-Horton; Consuelo Velazquez-Acosta; Diana Vilar-Compte
Journal:  Support Care Cancer       Date:  2018-06-08       Impact factor: 3.603

5.  Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus.

Authors:  Jörg J Ruhe; Anupama Menon
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

6.  Incidence and prognosis of non-typhoid Salmonella bacteraemia in Denmark: a 10-year county-based follow-up study.

Authors:  K O Gradel; H C Schønheyder; L Pedersen; R W Thomsen; M Nørgaard; H Nielsen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-03       Impact factor: 3.267

7.  Empiric antibiotic therapy for Staphylococcus aureus bacteremia may not reduce in-hospital mortality: a retrospective cohort study.

Authors:  Marin L Schweizer; Jon P Furuno; Anthony D Harris; J Kristie Johnson; Michelle D Shardell; Jessina C McGregor; Kerri A Thom; George Sakoulas; Eli N Perencevich
Journal:  PLoS One       Date:  2010-07-02       Impact factor: 3.240

8.  Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization.

Authors:  Rebecca H Sunenshine; Marc-Oliver Wright; Lisa L Maragakis; Anthony D Harris; Xiaoyan Song; Joan Hebden; Sara E Cosgrove; Ashley Anderson; Jennifer Carnell; Daniel B Jernigan; David G Kleinbaum; Trish M Perl; Harold C Standiford; Arjun Srinivasan
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

9.  Staphylococcus aureus bacteriuria as a prognosticator for outcome of Staphylococcus aureus bacteremia: a case-control study.

Authors:  Shingo Chihara; Kyle J Popovich; Robert A Weinstein; Bala Hota
Journal:  BMC Infect Dis       Date:  2010-07-29       Impact factor: 3.090

10.  Racial differences in the impact of comorbidities on survival among elderly men with prostate cancer.

Authors:  Mary Putt; Judith A Long; Chantal Montagnet; Jeffrey H Silber; Virginia W Chang; J Sanford Schwartz; Craig Evan Pollack; Yu-Ning Wong; Katrina Armstrong
Journal:  Med Care Res Rev       Date:  2009-04-08       Impact factor: 3.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.